Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease
- PMID: 37451302
- DOI: 10.1016/S2352-3026(23)00185-0
Social determinants of health: the next frontier for improving care and outcomes in sickle cell disease
Conflict of interest statement
JSP is a member of the PhenX Toolkit Sickle Cell Disease Psychosocial and Social Determinants of Health Working Group and reports consulting fees from Forma Therapeutics. AMH reports a grant from the National Heart, Lung, and Blood Institute (NHLBI), and consulting fees from Global Blood Therapeutics. LEC is chair of the PhenX Toolkit Sickle Cell Disease Psychosocial and Social Determinants of Health Working Group. JSH reports grants from NHLBI, the American Society of Hematology (ASH) Foundation, Centers for Disease Control and Prevention, and Health Resources and Services Administration; consulting fees from Global Blood Therapeutics; and honoraria from Montefiori Medical Center, UpToDate, ASH, Cook Children's Medical Center, International Association of Sickle Cell Nurses and Professional Associates, University of Massachusetts Medical School, and University of Utah; and is a board member of the Sickle Cell Foundation of Maryland.
Comment on
-
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.Lancet Haematol. 2023 Aug;10(8):e633-e686. doi: 10.1016/S2352-3026(23)00096-0. Epub 2023 Jul 11. Lancet Haematol. 2023. PMID: 37451304 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
